John E. Elicker | Bristol-Myers Squibb Co. |
Giovanni Caforio | Bristol-Myers Squibb Co. |
Charles A. Bancroft | Bristol-Myers Squibb Co. |
Murdo Gordon | Bristol-Myers Squibb Co. |
Thomas J. Lynch, Jr., M.D. | Bristol-Myers Squibb Co. |
Jason M. Gerberry | Bank of America Merrill Lynch |
Christopher Schott | JPMorgan Securities LLC |
Jami Rubin | Goldman Sachs & Co. LLC |
Umer Raffat | Evercore ISI |
Andrew S. Baum | Citigroup Global Markets Ltd. |
John T. Boris | SunTrust Robinson Humphrey, Inc. |
Geoffrey Meacham | Barclays Capital, Inc. |
Timothy Minton Anderson | Sanford C. Bernstein & Co. LLC |
Matthew Phipps | William Blair & Co. LLC |
Gregg Gilbert | Deutsche Bank Securities, Inc. |
Vamil K. Divan | Credit Suisse Securities (NYSE:USA) LLC |
David R. Risinger | Morgan Stanley & Co. LLC |
Steve Scala | Cowen & Co. LLC |
Good day, and welcome to the Bristol-Myers Squibb 2018 first quarter results conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. John Elicker, Senior Vice President, Public Affairs and Investor Relations. Please go ahead, sir.